The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …

There is increasing interest in defining the location, content, and role of extracellular matrix
(ECM) components in brain structure and function during development, aging, injury, and …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease.
Phosphorylated tau accumulation causes synaptic impairment, neuronal dysfunction and …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …

Microglia-mediated synaptic loss contributes to the development of cognitive impairments in
Alzheimer's disease (AD). However, the basis for this immune-mediated attack on synapses …

DNA damage contributes to brain aging and neurodegenerative diseases. However, the
factors stimulating DNA repair to stave off functional decline remain obscure. We show that …

Protein N-glycosylation plays critical roles in controlling brain function, but little is known
about human brain N-glycoproteome and its alterations in Alzheimer's disease (AD). Here …

Alzheimer's Disease (AD) is a neurodegenerative disease that affects cognition and is the
most common cause of dementia in the elderly. As the number of elderly individuals …